Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - propofol, quantity: 1000 mg - injection, emulsion - excipient ingredients: egg lecithin; soya oil; sodium oleate; water for injections; sodium hydroxide; glycerol - short acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and children aged three years and older. provive 1% has no analgesic properties. although the safety and efficacy of propofol in paediatric day surgery have not been demonstrated, it may also be a useful agent in this setting and its use should not be precluded. provive 1% may also be used in adults for sedation of ventilated patients receiving intensive care. provive 1% may also be used in adults for monitored conscious sedation and diagnostic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - propofol, quantity: 500 mg - injection, emulsion - excipient ingredients: soya oil; water for injections; egg lecithin; sodium oleate; glycerol; sodium hydroxide - short acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and children aged three years and older. provive 1% has no analgesic properties. although the safety and efficacy of propofol in paediatric day surgery have not been demonstrated, it may also be a useful agent in this setting and its use should not be precluded. provive 1% may also be used in adults for sedation of ventilated patients receiving intensive care. provive 1% may also be used in adults for monitored conscious sedation and diagnostic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - propofol, quantity: 200 mg - injection, emulsion - excipient ingredients: sodium oleate; egg lecithin; glycerol; water for injections; soya oil; sodium hydroxide - short acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and children aged three years and older. provive 1% has no analgesic properties. although the safety and efficacy of propofol in paediatric day surgery have not been demonstrated, it may also be a useful agent in this setting and its use should not be precluded. provive 1% may also be used in adults for sedation of ventilated patients receiving intensive care. provive 1% may also be used in adults for monitored conscious sedation and diagnostic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - propofol, quantity: 1000 mg - injection, emulsion - excipient ingredients: water for injections; glycerol; soya oil; medium chain triglycerides; sodium oleate; egg lecithin; sodium hydroxide - short acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and children aged three years and older. provive mct-lct 1% has no analgesic properties. although the safety and efficacy of propofol in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. provive mct-lct 1% may also be used in adults for sedation of ventilated patients receiving intensive care. provive mct-lct 1% may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - propofol, quantity: 500 mg - injection, emulsion - excipient ingredients: glycerol; soya oil; sodium hydroxide; medium chain triglycerides; water for injections; egg lecithin; sodium oleate - short acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and children aged three years and older. provive mct-lct 1% has no analgesic properties. although the safety and efficacy of propofol in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. provive mct-lct 1% may also be used in adults for sedation of ventilated patients receiving intensive care. provive mct-lct 1% may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - propofol, quantity: 200 mg - injection, emulsion - excipient ingredients: medium chain triglycerides; sodium oleate; glycerol; sodium hydroxide; water for injections; egg lecithin; soya oil - short acting intravenous anaesthetic agent suitable for induction and maintenance of general anaesthesia in adults and children aged three years and older. provive mct-lct 1% has no analgesic properties. although the safety and efficacy of propofol in paediatric day surgery have not been demonstrated, it may be a useful agent in this setting and its use should not be precluded. provive mct-lct 1% may also be used in adults for sedation of ventilated patients receiving intensive care. provive mct-lct 1% may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.